With the U.S. economic landscape remaining uncertain, it's prudent to add a defensive stock or two to your portfolio, and with the aforementioned in mind Alliant Techsystems is worth an evaluation.
Alliant Techsystems (NYSE: ATK) is an ammunition supplier and rocket engine / motor manufacturer with substantial United States Government contracts.
Analysts like Alliant's strong fundamentals, solid U.S. Department of Defense orders for ammunition, equally impressive launch systems work from NASA, and sporting ammunition business.
Analysts also believe ATK is well-positioned to capture a portion of the U.S. DOD's work for next-generation weapon systems.
Meanwhile, margins should improve slightly in F2008 to 11%, and costs, while not low, are reasonable. The Reuters F2008/F2009 EPS consensus estimates for ATK are $6.39/$7.38.
The risks? An early withdrawal of U.S troops from Iraq would lower ATK's revenue for F2009-F2010. Analysts are also keeping an eye on the company's productivity per man hour.
The First Call mean rating for ATK is: Buy. [12 firms.] Mean 2008 target: $128. [high: $136, low: $120.]
Stock Analysis: Alliant Techsystems is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than 2 years should be rewarded from ATK's shares. Sell / Stop Loss if you were to purchase shares in this company: $68.
Disclosure: Lazzaro has no positions in stocks. In addition to private real estate holdings, he owns corporate and municipal bonds, and cash certificates of deposit.
Last updated: February 10, 2012: 09:22 AM
Hot Stocks
DailyFinance Headlines
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
Benzinga Headlines
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
TheFlyOnTheWall.com Headlines
- Omnicom management to meet with JPMorgan
- NetApp volatility elevated into Q3 and growth outlook
- EMRISE and lender amend loan terms; allows dicount payoff up to 30%
- Alexion target raised to $90 from $76 at ThinkEquity
- Actuant management to meet with JPMorgan
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

